Screener
Nuvation Bio NUVB CN — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:55 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336646
| Line item | For the three months ended June 30, 2026 | For the three months ended June 30, 2025 | For the six months ended June 30, 2026 | For the six months ended June 30, 2025 |
|---|---|---|---|---|
| United States | $23,192 | $1,238 | $100,579 | $1,238 |
| China | 7,991 | 3,354 | 13,180 | 6,254 |
| Japan | 504 | 241 | 1,156 | 425 |
| Total revenue | $31,687 | $4,833 | $114,915 | $7,917 |
Item 1. Financial Statements.
FAQ
- What is Nuvation Bio's CN — revenue?
- Nuvation Bio (NUVB) reported CN — revenue of $7.99M in Q2 2026.
- How has Nuvation Bio's CN — revenue changed year-over-year?
- Nuvation Bio's CN — revenue increased by 138.3% year-over-year, from $3.35M to $7.99M.
- What does CN — revenue mean?
- This metric represents the total gross income generated by the company's operations within the specified geographic segment. It reflects the market demand and commercial success of the company's therapeutic offerings in this region. Monitoring this figure helps investors assess the company's regional growth trajectory and market penetration.
Ask your AI about Nuvation Bio's cn — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude